Results
1 -
10 of
92Zeng Fanxun, Qi Tiantian, Li Chunyan, Li Tingfang, Li Honglin, Li Shiliang, Zhu Lili, Xu Xiaoyong.
Synthesis, structure–activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase, Med. Chem. Commun., 2017 Persistence to oral disease-modifying therapies in multiple sclerosis patients, Journal of Neurology Emerging Oral Therapies in Multiple Sclerosis, Current Neurology and Neuroscience Reports Multiple sclerosis therapies and pregnancy, Case Studies in Multiple Sclerosis The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis, Current Neurology and Neuroscience Reports Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis, CNS Drugs No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsingu2013Remitting Multiple Sclerosis, Advances in Therapy Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity, Journal of Neuroinflammation Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review, BMC Neurology Zeigen die neuen oralen Therapien Vorteile in der Basistherapie der Multiplen Sklerose? Pro, Der Nervenarzt